<DOC>
	<DOCNO>NCT00728715</DOCNO>
	<brief_summary>Some study conclude high-dose inhaled steroid ( IS ) effective clinical control patient bronchiectasis , however high dos need provokes adverse effect low dos effective . Combined treatment budesonide formoterol demostrated effective patient asthma COPD achieve reduction steroid dose thanks adition long-acting beta 2 agonist . There study literature analyse effect combine treatment patient bronchiectasis . The objective study compare efficacy safety formoterol-medium dose budesonide single inhaler versus high-dose budesonide clinical control patientes non-cystic fibrosis bronchiectasis . Study Design : Randomized ( 3 month ) parallel group study . Patients : Patients bronchiectasis diagnose high-resolution CT scan chronic obstructive airway obstruction . Exclusion : Asthma current past smoker . Methods : Run period patient high dose budesonide ( 1600 mcg/day ) 3 month . After , randomization two group : 1 . The treatment ( 1600 mcg/day budesonide ) combine treatment lower dose budesonide ( 18 mcg/day formoterol 800 mcg budesonide ) single turbuhaler inhaler 3 month . Studied variable : Clinical , functional , quality life , microbiological number side effect .</brief_summary>
	<brief_title>Efficacy Budesonide-Formoterol Bronchiectasis</brief_title>
	<detailed_description />
	<mesh_term>Bronchiectasis</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<criteria>1880 year old patient diagnose noncystic fibrosis bronchiectasis More 1 pulmonary lobe affect Chronic obstructive airflow obstruction Stable phase disease Asthma , COPD current/past smnokers No consent Known intolerance budesonide formoterol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Budesonide</keyword>
	<keyword>Formoterol</keyword>
	<keyword>Non cystic fibrosis bronchiectasis</keyword>
</DOC>